Is there a stronger graft-versus-leukemia effect using HLA-haploidentical donors compared with HLA-identical siblings?

摘要: Haploidentical hematopoietic stem cell transplants (HSCTs) are increasingly used, but it is unknown whether they have a stronger graft-versus-leukemia (GVL) effect. We analyzed 10 679 acute leukemia patients who underwent HSCT from an HLA-matched sibling donor (MSD, n=9815) or haploidentical (⩾2 HLA-antigen disparity, n=864) between 2007 and 2012, reported to the European Group for Blood Marrow Transplantation. In Cox regression model, chronic graft-versus-host disease (GVHD) was added as time-dependent variables. There no difference in probability of relapse recipients MSD grafts. Factors importance after T-cell-replete grafts included remission status at HSCT, Karnofsky score ⩽80, GVHD grade II higher (P<10(-5)). Patients with post-transplant cyclophosphamide (n=194) had similar outcome other (n=369). Non-relapse mortality significantly group compared that Leukemia-free survival superior receiving (P<10(-5)) T-cell-depleted (P=0.0006). The risk same received those given transplants, suggesting GVL